- Exploring efficiencies from eTMF with Cancer Research UK
- FDA accelerated review denial is a blow to Spectrum’s poziotinib
- New drugs and therapeutic options help the immune system fight cancer
- Roche’s Tecentriq threatens BMS’ Opdivo in small cell lung cancer market
- The challenges of using stem cells in neurology
IQVIA unveils new global site network to increase trial opportunities
IQVIA, a life sciences technology solutions provider, has launched a technology-based global site network that opens opportunities for more clinical trials at experienced clinical and research sites.
Favilavir approved as experimental coronavirus drug
Zhejiang Hisun Pharmaceutical’s anti-viral drug Favilavir (Favipiravir) has been approved as an investigational therapy to treat the coronavirus, reported local media.
New clinical trial firm Curavit Clinical Research officially launches
A new clinical trials company, Curavit Clinical Research, has been launched to help realise the potential of decentralised clinical trials.
UCL researchers test cough syrup drug for Parkinson’s
A research team at University College London has secured funding to evaluate the use of cough syrup drug ambroxol to treat Parkinson’s disease patients in clinical trials.
Uniquid advantages of SOMAI PRO include identification of new mechanisms of action of drugs (biological activity defined by Molecular Field Maps, which were not described before and non-structural analogues identification reliable patent protection.
January’s top news stories
A Phase I clinical trial of monoclonal antibody (mAb) CIS43LS against malaria started the enrolment of healthy adults at the NIH Clinical Center in Bethesda, Maryland, US, and Acceleron Pharma reported that the Phase II PULSAR study of sotatercept achieved its primary and major secondary endpoints for the treatment of pulmonary arterial hypertension (PAH). Clinicaltrialsarena.com wraps up key headlines from January 2020.
Ethical GmbH upgrades eAdjudication®
Ethical GmbH upgrades the study designer functionality available with the eAdjudication® software platform to allow customers to independently create and configure new studies in their company dedicated workspace.